AIM: The mutations in two breast cancer susceptibility genes, BRCA1 and BRCA2, are frequently associated with familial breast cancer. In this study, we aimed to inves-tigate the probable founder mutations of BRCA1 and BRCA2 genes in Iranian breast cancer patients. METHODS: The total 400 patients affected with primary breast cancer were included in this study. Mutation detection was carried out on the basis of a PCR-based amplifi-cation, and two founder mutations for BRCA1 (185delAG and 5382insC) and one for BRCA2 (6174delT) were screened and considered by pedigree analysis. RESULTS: The positive family histories of breast cancer and other malignancies were recorded in 27.5 % and 52 % of patient pedigrees, respectively. The most frequent occ...
International audienceABSTRACT: Breast cancer is the most prevalent malignancy in women in Western c...
Introuduction: Breast cancer is the most common malignancy in women and affects approximately 1 out ...
To date, BRGA1 and BRCA2 mutations in breast and/or ovarian patients have not been characterized in ...
AIM: The mutations in two breast cancer susceptibility genes, BRCA1 and BRCA2, are frequently assoc...
Purpose: Germline mutations in either BRCA1 or BRCA2 genes are responsible for the majority of hered...
Background: Breast cancer is the most common cause of death among women in the world and in Iran. A ...
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives...
BACKGROUND: BRCA1 and BRCA2 are the two major susceptibility genes involved in hereditary breast can...
Hereditary breast cancer accounts for 3-8% of all breast cancers, with mutations in the BRCA1 and BR...
ABSTRACT Mutations of breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 ) are the most wel...
Breast cancer is the most frequent malignancy diagnosed in women in the western world, affecting app...
Background. Breast cancer is one of the most common cancers in women worldwide. The germline mutatio...
PubMedID: 31228304Certain genetic predisposition factors, such as BRCA1 and BRCA2 mutations play a p...
Background:Both BRCA1 and BRCA2 are tumor suppressor gene and are inherited as an autosomal dominant...
Abstract Background Breast cancer is one of the most common diseases affecting women. Inherited susc...
International audienceABSTRACT: Breast cancer is the most prevalent malignancy in women in Western c...
Introuduction: Breast cancer is the most common malignancy in women and affects approximately 1 out ...
To date, BRGA1 and BRCA2 mutations in breast and/or ovarian patients have not been characterized in ...
AIM: The mutations in two breast cancer susceptibility genes, BRCA1 and BRCA2, are frequently assoc...
Purpose: Germline mutations in either BRCA1 or BRCA2 genes are responsible for the majority of hered...
Background: Breast cancer is the most common cause of death among women in the world and in Iran. A ...
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives...
BACKGROUND: BRCA1 and BRCA2 are the two major susceptibility genes involved in hereditary breast can...
Hereditary breast cancer accounts for 3-8% of all breast cancers, with mutations in the BRCA1 and BR...
ABSTRACT Mutations of breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 ) are the most wel...
Breast cancer is the most frequent malignancy diagnosed in women in the western world, affecting app...
Background. Breast cancer is one of the most common cancers in women worldwide. The germline mutatio...
PubMedID: 31228304Certain genetic predisposition factors, such as BRCA1 and BRCA2 mutations play a p...
Background:Both BRCA1 and BRCA2 are tumor suppressor gene and are inherited as an autosomal dominant...
Abstract Background Breast cancer is one of the most common diseases affecting women. Inherited susc...
International audienceABSTRACT: Breast cancer is the most prevalent malignancy in women in Western c...
Introuduction: Breast cancer is the most common malignancy in women and affects approximately 1 out ...
To date, BRGA1 and BRCA2 mutations in breast and/or ovarian patients have not been characterized in ...